Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MATTHEW JOHN HERRMANN

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1508251091
CMS profile
2264417
Location
PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$3,397.36

158 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,297.37 157
Education $99.99 1

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 158 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MATTHEW JOHN HERRMANN

NPI 1508251091 · CMS profile ID 2264417

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 158 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1508251091?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MATTHEW JOHN HERRMANN, NPI 1508251091, CMS profile ID 2264417. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 158 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508251091?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MATTHEW JOHN HERRMANN, NPI 1508251091, CMS profile ID 2264417. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 158 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508251091?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MATTHEW JOHN HERRMANN, NPI 1508251091, CMS profile ID 2264417, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 158 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1508251091?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

158 matching records · $3,397.36 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 158 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 158.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $9.0704/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227151967 CMS
Amgen Inc. $14.2704/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227151975 CMS
Amgen Inc. $5.4104/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227151957 CMS
Amgen Inc. $22.4004/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228276697 CMS
Janssen Scientific Affairs, LLC $43.6704/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174149579 CMS
ABBVIE INC. $7.9904/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202039131 CMS
ABBVIE INC. $14.8704/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202039129 CMS
ABBVIE INC. $16.9104/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202039127 CMS
ABBVIE INC. $23.8504/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202039125 CMS
Amgen Inc. $13.9004/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227151965 CMS
E.R. Squibb & Sons, L.L.C. $20.9504/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184684196 CMS
Novartis Pharmaceuticals Corporation $4.3204/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200236716 CMS
ABBVIE INC. $1.2304/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202039123 CMS
Novartis Pharmaceuticals Corporation $3.6803/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200236714 CMS
PFIZER INC. $20.6203/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230061325 CMS
ABBVIE INC. $4.5903/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202039119 CMS
ABBVIE INC. $13.9803/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202039121 CMS
Amgen Inc. $10.3903/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227151989 CMS
ABBVIE INC. $28.8903/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202039117 CMS
PFIZER INC. $20.6203/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230062485 CMS
ABBVIE INC. $22.5103/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202039115 CMS
Amgen Inc. $15.1403/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228276713 CMS
Amgen Inc. $10.7403/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227151959 CMS
Ferring Pharmaceuticals Inc. $18.7703/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242069127 CMS
ABBVIE INC. $21.3303/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202039113 CMS
Amgen Inc. $16.7402/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228276705 CMS
Novartis Pharmaceuticals Corporation $29.3402/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200236712 CMS
ABBVIE INC. $16.7902/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202039111 CMS
ABBVIE INC. $20.7802/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202039109 CMS
Alexion Pharmaceuticals, Inc. $15.5202/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202969630 CMS
Genentech USA, Inc. $20.4902/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211546874 CMS
PFIZER INC. $14.3502/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230136186 CMS
Genentech USA, Inc. $28.5902/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211546871 CMS
Fresenius Kabi USA, LLC $22.9902/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250525070 CMS
Amgen Inc. $20.7402/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228276715 CMS
UCB, Inc. $38.5002/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224518211 CMS
Amgen Inc. $18.2002/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228276723 CMS
ABBVIE INC. $19.8702/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202039107 CMS
Novartis Pharmaceuticals Corporation $19.8302/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200236710 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $24.9802/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223008720 CMS
GlaxoSmithKline, LLC. $13.9201/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190836174 CMS
Novartis Pharmaceuticals Corporation $17.7301/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200236708 CMS
Amgen Inc. $14.3201/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227151995 CMS
ABBVIE INC. $13.5401/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202039105 CMS
ABBVIE INC. $7.5001/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202039101 CMS
ABBVIE INC. $5.0001/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202039103 CMS
Amgen Inc. $9.9901/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227151955 CMS
ABBVIE INC. $16.3601/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202039099 CMS
ABBVIE INC. $19.0401/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202039095 CMS
ABBVIE INC. $7.2201/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202039097 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $103.85 1
PY2021 $1,002.71 43
PY2022 $254.25 3
PY2023 $3,845.00 142
PY2024 $2,630.44 138
PY2025 $3,397.36 158

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $348,017.80 16
PY2024 Recipient $37,402.58 2
PY2024 Principal investigator $49,009.15 11

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

16 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 UCB SA $31,640.00 11/27/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1246659018
Principal investigator 1 GlaxoSmithKline, LLC. $1,725.00 08/27/2025 Non-covered Recipient Entity
ADVARRA
THE EVALUATION OF USE OF BELIMUMAB IN ROUTINE CARE SETTINGS IN LUPUS N No dispute reported 06/30/2026 1192182223
Principal investigator 1 Eli Lilly and Company $14,000.00 06/23/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187880727
Principal investigator 1 Janssen Research & Development, LLC $2,736.00 06/20/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY RE SEARCH PLLC
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175395900
Principal investigator 1 Eli Lilly and Company $26,948.00 06/16/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A PHASE 2A, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3541860 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187874633
Principal investigator 1 Janssen Research & Development, LLC $10,288.00 06/13/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY RE SEARCH PLLC
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175396069
Principal investigator 1 Amgen Inc. $8,297.10 06/04/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgren's Syndrome No dispute reported 06/30/2026 1246639239
Principal investigator 1 UCB SA $22,874.98 05/19/2025 Non-covered Recipient Entity
Arizona Arthritis And Rheumatology Associates, Pc
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1246658250
Principal investigator 1 Eli Lilly and Company $1,537.59 04/23/2025 Non-covered Recipient Entity
AARA CLINICAL RESEARCH
A PHASE 2A, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3541860 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187873185
Principal investigator 1 Janssen Research & Development, LLC $5,353.00 04/18/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY RE SEARCH PLLC
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175396341
Principal investigator 1 Amgen Inc. $104,125.50 04/09/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgren's Syndrome No dispute reported 06/30/2026 1246639277
Principal investigator 1 Janssen Research & Development, LLC $90.00 03/28/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY RE SEARCH PLLC
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175396346
Principal investigator 1 Janssen Research & Development, LLC $10,125.00 02/24/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY RE SEARCH PLLC
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175396319
Principal investigator 1 Eli Lilly and Company $1,747.37 01/27/2025 Non-covered Recipient Entity
AARA CLINICAL RESEARCH
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187875725
Principal investigator 1 Amgen Inc. $156.26 01/10/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY ASSOCIATES - GLENDALE - 5681 W BEVERLY LN
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgren's Syndrome No dispute reported 06/30/2026 1246639207
Principal investigator 1 Eli Lilly and Company $106,374.00 01/07/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187877155